Ebola vaccine
Candidate Ebola vaccine being given | |
| Vaccine description | |
|---|---|
| Target | Ebola virus |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | Ervebo, Zabdeno, Mvabea |
| AHFS/Drugs.com | Monograph |
| License data |
|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
An Ebola vaccine is a vaccine used to prevent Ebola virus disease (Ebola). As of 2022, there are only two vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States is rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates (usually macaques) against lethal infection.
Vaccines include replication-deficient adenovirus vectors, replication-competent vesicular stomatitis (VSV) and human parainfluenza (HPIV-3) vectors, and virus-like nanoparticle preparations.
The Ebola vaccine is on the World Health Organization's List of Essential Medicines.